Outsourcing-Pharma

For over 16 years, William Reed’s Outsourcing-Pharma has been the top online news platform for the pharmaceutical industry, utilizing a digital-first approach to deliver valuable insights and comprehensive information that supports your business growth. Outsourcing-Pharma provides thorough coverage of the pharmaceutical sector, offering industry experts the latest news on clinical trials, commercial development, and the production of small molecule drugs. Our editorial standards are exceptional, and we share engaging content through various channels, ensuring it reaches the right audience no matter where they are.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#2185027

United States

#1324063

Health/Biotechnology and Pharmaceuticals

#1250

Traffic sources

Monthly visitors

Articles

Ethris reports positive phase 1 results for ETH47 mRNA asthma treatment

2 months ago | outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith

Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy is intended for the treatment of uncontrolled asthma, a condition where asthma symptoms are frequent and disruptive, often due to a virus infection. The mechanism of action of ETH47 aims to prevent the symptoms of uncontrolled asthma at the source by inducing an innate immune response at the point of entry of viruses.
Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline

2 months ago | outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández

The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which is expected to close in late 2025, is intended to absorb Evergreen’s manufacturing capabilities and radiopharmaceutical pipeline.
Manas AI bags $24.6 million to turbocharge drug discovery

2 months ago | outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws

The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic investors. Manas will use the proceeds to scale up its AI technology and drive ahead its drug pipeline programs. Manas AI is one of many startups gunning to address the costly and risky process of drug development, with more than 90% of drug candidates failing to reach the market from the preclinical stage.
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials

2 months ago | outsourcing-pharma.com | Clara Fernandez |Clara Fernández

Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major competitors in the weight loss drug market.
The largest pharma acquisitions of 2024

Jan 23, 2025 | outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws

Compared to the previous years, 2024 has been a relatively slow year for mergers and acquisitions in the pharmaceutical space. The largest acquisition of 2024 doesn’t nearly match Pfizer’s acquisition of Seagen for $43 billion in 2023, or Amgen’s Horizon buyout for $27.8 billion in 2022.
Novo Nordisk reports positive results for high-dose Wegovy formulation

Jan 21, 2025 | outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws

Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both formulations were delivered subcutaneously once a week and were accompanied by lifestyle changes.
Lindus Health: AI instrumental for predicting trial outcomes and shaping study design

Jan 20, 2025 | outsourcing-pharma.com | Liza Laws

We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025What are the most significant milestones your company achieved in 2024, and how have they impacted your organization or the industry? The most important thing is the trials we’re running for our sponsors. We’re operating studies for groundbreaking interventions in oncology, neurology, diagnostics, and other therapeutic areas, and it’s amazing to be part of the process.
SCOPE 2025: Spotlight on clinical trial technology

Jan 17, 2025 | outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith

Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market for clinical trials is expected to grow to over $106 bn by 2032, but stakeholders in this industry face increasingly challenging obstacles, including regulatory hurdles, talent shortages and clinical studies becoming significantly larger, longer, and more complex.
Overcoming clinical trial obstacles with AI: WCG’s outlook for SCOPE 2025

Jan 16, 2025 | outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws

As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2 billion in 2023 to $73.2 billion in 2028, partly driven by soaring demand for outsourced trial providers. However, clinical trial providers are facing challenges in completing trials efficiently, including long trial durations, increased competition for sites and participants, and complex protocols.
Decentralized clinical trials take the spotlight at SCOPE 2025

Jan 16, 2025 | outsourcing-pharma.com | Clara Fernandez |Clara Fernández

Stakeholders across the clinical trials and digital health industry will be gathering next month in Orlando at the Summit for Clinical OPS Executives (SCOPE) 2025. With decentralized clinical trials increasingly gathering attention in the pharmaceutical industry, accompanied by rapid market growth, advancements in this area will be one of the major topics of discussion during the event.